Myriad gains from strong diagnostic sales
This article was originally published in Clinica
Executive Summary
Myriad Genetics continues to benefit from its fast-growing molecular diagnostics business, which helped the company achieve high double-digit revenue growth and significantly narrow its net loss for fiscal 2007.